Exact Imaging reported it has closed on $10 million in financing in a round led by iGan Partners. The Toronto-based company ...

A newer type of prostate cancer scan called 64 Cu-SAR-bisPSMA found more than twice as many cancer spots as a commonly used PSMA PET scan in men whose prostate-specific antigen (PSA) was rising after ...

When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...

A new imaging technique developed at Memorial Sloan Kettering Cancer Center (MSK) shows promise for detecting deadly forms of lung cancer and prostate cancer. The technology uses a radioactive ...

New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from ...

At a per-patient level, 68 Ga-PSMA-11 identified 36% (18/50) of trial participants as having a positive scan, while 64 Cu-SAR-bisPSMA next-day imaging detected prostate cancer in 78% (39/50) of cases.

A new imaging approach developed by researchers at Heriot-Watt University has shown "extremely encouraging" results in early-stage clinical trials on prostate cancer at the Western General Hospital in ...

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after the successful development of a new alpha-ray therapeutic agent ...

In metastatic prostate cancer, AI-facilitated quantification of metastatic burden, accurate identification of castration resistance, and prediction of treatment sensitivity and resistance are active ...

Exact Imaging, a leader in high-resolution micro-ultrasound for urologic imaging, today announced the closing of a $10 million financing round led by iGan Partners. Proceeds from the financing will be ...